|
[1]
|
Effort-related effects of chronic administration of the DA D2 receptor antagonist haloperidol via subcutaneous programmable minipumps: Reversal by co-administration of the adenosine A2A antagonist istradefylline
Psychopharmacology,
2023
DOI:10.1007/s00213-023-06439-y
|
|
|
|
|
[2]
|
Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios
Degenerative Neurological and Neuromuscular Disease,
2022
DOI:10.2147/DNND.S245197
|
|
|
|
|
[3]
|
Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease
Expert Review of Neurotherapeutics,
2021
DOI:10.1080/14737175.2021.1880896
|
|
|
|
|
[4]
|
Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST)
Parkinsonism & Related Disorders,
2021
DOI:10.1016/j.parkreldis.2021.09.015
|
|
|
|
|
[5]
|
Neurobiology and pharmacology of activational and effort-related aspects of motivation: rodent studies
Current Opinion in Behavioral Sciences,
2018
DOI:10.1016/j.cobeha.2018.01.026
|
|
|
|
|
[6]
|
Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression
Frontiers in Pharmacology,
2018
DOI:10.3389/fphar.2018.00526
|
|
|
|
|
[7]
|
New Developments on the Adenosine Mechanisms of the Central Effects of Caffeine and Their Implications for Neuropsychiatric Disorders
Journal of Caffeine and Adenosine Research,
2018
DOI:10.1089/caff.2018.0017
|
|
|
|
|
[8]
|
The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation
Pharmacological Reviews,
2018
DOI:10.1124/pr.117.015107
|
|
|
|
|
[9]
|
New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson’s Disease
Current Pharmacology Reports,
2016
DOI:10.1007/s40495-016-0071-0
|
|
|
|